The rate of all grade neutropenia 47/58 (81.0%) and febrile neutropenia 8/58 (13.8%) were higher in patients receiving secondary G‐CSF as compared to primary prophylaxis [42/83 (50.6%) and 7/83 (8.4%)] (not presented in the table). This evidence concerns the gene CSF3 and neutropenia.